Genmab — Maj 2020
-
bestyrelse får ikke warrants, de får restricted stocks
-
på hjemmesiden, investors, Corporate Governance, findes compensation report, hvor detaljer findes får dem der har lyst...
-
EHA abstracts available via https://library.ehaweb.org/eha/#!*listing=1*browseby=3*sortby=2*ce_id=1550*search=daratumumab
-
SUPERIOR ANTI-TUMOR ACTIVITY OF HEXABODY
-CD38 IN PRECLINICAL MODELS OF MULTIPLE MYELOMA, B CELL LYMPHOMA AND ACUTE MYELOID LEUKEMIA https://library.ehaweb.org/eha/2020/eha25th/294801/ida.h.hiemstra.superior.anti-tumor.activity.of.hexabody-cd38.in.preclinical.html?f=listing%3D1*browseby%3D8*sortby%3D2*media%3D3*ce_id%3D1766*ot_id%3D23230*search%3Ddaratumumab*marker%3D757 -
SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: DOSE-ESCALATION DATA FROM A PHASE 1/2 TRIAL https://library.ehaweb.org/eha/2020/eha25th/293707/martin.hutchings.subcutaneous.epcoritamab.28gen3013.cd3xcd2029.in.patients.with.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab
-
EVALUATION OF PHARMACODYNAMIC BIOMARKERS OF EPCORITAMAB (GEN3013; CD3XCD20): RESULTS FROM A PHASE 1/2 DOSE-ESCALATION STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab
-
-
Tak for links E L.
-
DUOHEXABODY
-CD37 SHOWS POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL B-CELL LYMPHOMA MODELS IN VITRO AND IN VIVO https://library.ehaweb.org/eha/2020/eha25th/293801/marije.b.overdijk.duohexabody-cd37.shows.potent.anti-tumor.activity.in.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dduohexabody -
tak Pensionisten - 15:14
-
A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) https://library.ehaweb.org/eha/2020/eha25th/295026/marie-victoria.mateos.a.phase.1.study.of.teclistamab.a.humanized.b-cell.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dteclistamab
-
Janssens bcma car-t har 100% ORR, 86% sCR men eet dødsfald pga CRS. http://johnsonandjohnson.gcs-web.com/static-files/8d6cdaa2-dcfb-4e49-9151-fcd8162f2df5
-
"CD38-knockout NK cells, which have been designed in attempt to prevent fratricide and enhance the activity of daratumumab" https://twitter.com/MM_Hub/status/1260948019689795589
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind